DYN - Dyne Therapeutics, Inc.

Insider Sale by Rhodes Jason P (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Rhodes Jason P, serving as Dir at Dyne Therapeutics, Inc. (DYN), sold 384,549 shares at $18.47 per share, for a total transaction value of $7,101,120.00. Following this transaction, Rhodes Jason P now holds 1,206,026 shares of DYN.

This sale represents a 24.00% decrease in Rhodes Jason P's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 23, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 27, 2026, 4 days after the trade was made.

Dyne Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Rhodes Jason P

Dir

Jason P. Rhodes is a Partner at Atlas Venture, where he focuses on creating and building novel therapeutics companies.[[1]](https://atlasventure.com/team/jason-rhodes/)[[2]](https://www.k36tx.com/jason-rhodes) He serves as Chairman of the Board at Dyne Therapeutics, Inc. (NASDAQ: DYN), a company he co-founded in 2017 and previously led as CEO, specializing in targeted therapies for genetically driven neuromuscular diseases.[[1]](https://atlasventure.com/team/jason-rhodes/)[[6]](https://www.dyne-tx.com/about-us/)[[7]](https://www.marketscreener.com/insider/JASON-RHODES-A0D895/) Rhodes recently traded shares as a Director at DYN.[user_query] His career highlights include founding and leading multiple biotech firms, such as Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals (Executive Chair), and Disarm Therapeutics (acquired by Eli Lilly), as well as board roles at companies like Accent Therapeutics, K36 Therapeutics, Replimune (NASDAQ: REPL), and others.[[1]](https://atlasventure.com/team/jason-rhodes/)[[2]](https://www.k36tx.com/jason-rhodes)[[3]](https://rectifypharma.com/team/jason-rhodes/) Previously, he was President of Epizyme (NASDAQ: EPZM), guiding it from research-stage to IPO, held business development roles at Alnylam Pharmaceuticals (NASDAQ: ALNY), and co-founded Fidelity Biosciences (now F-Prime Capital), leading investments like FoldRx (acquired by Pfizer).[[1]](https://atlasventure.com/team/jason-rhodes/)[[3]](https://rectifypharma.com/team/jason-rhodes/)[[4]](https://ventures.yale.edu/our-team/jason-rhodes-mba) Rhodes holds an M.B.A.[[4]](https://ventures.yale.edu/our-team/jason-rhodes-mba)

View full insider profile →

Trade Price

$18.47

Quantity

384,549

Total Value

$7,101,120.00

Shares Owned

1,206,026

Trade Date

Thursday, April 23, 2026

5 days ago

SEC Filing Date

Monday, April 27, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning DYN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5996454

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime